None listed
Conditions
Brief summary
This clinical investigation aims to evaluate the performance and safety of the microICSI device, an investigational product designed to improve the specialised in vitro fertilization (IVF) process of intracytoplasmic sperm injection (ICSI) by reducing physical trauma to oocytes during insemination. The microICSI device uses cutting-edge micro-3D printing technology (2-photon polymerization) to create a micron-level resolution 3D receptacle, minimizing the need for the conventional (glass) holding pipette and suction, which often causes distortion to the oocyte’s shape. This innovation seeks to enhance fertilisation and embryo development outcomes, while also reducing variability associated with traditional ICSI procedures. The primary hypothesis is that microICSI will demonstrate non-inferior performance to cICSI regarding fertilization outcomes.
Interventions
This clinical investigation aims to evaluate the performance and safety of the microICSI device, an investigational product designed to improve the specialised in vitro fertilization (IVF) process of intracytoplasmic sperm injection (ICSI) by reducing physical trauma to oocytes during insemination. The microICSI device is comprised of a square dish base with angled corners, an insert and a lid. The dish size is 65.00 mm x 65.00 mm. The microICSI device with be used by experienced embryologists in a clinical setting. Full product training will be conducted prior to use. The participants will under pre-treatment and enrolment procedures, ensuring that inclusion and exclusion criteria and fully met prior to signed consent. Fresh or frozen sperm will be collected, and a minimum of six oocytes. Half the oocytes will be administered for microICSI, with the other half being used for cICSI. The clinical monitor will ensure adherence to all aspects of the trial, via clinical monitoring visits and validation of data in the EDC. If multiple oocytes progress to blastocyst stage, the best quality blastocyst will be selected for embryo transfer, as per standard best practice.
Sponsors
Study design
Eligibility
Inclusion criteria
Patients intending to undergo ICSI where there are: - no medical contraindications to perform the treatment. - 6 or more mature oocytes at the time of cumulus cell removal. - Signed informed consent form prior to any study-related procedures.
Exclusion criteria
- Individuals under the age of 18 or age of legal consent <6 mature oocytes at the time of cumulus removal - Fertility preservation patients - Previous participation in the study - Patients with surrogates/gestational carriers - Artificial oocyte activation - Frozen oocytes - Testicular biopsy with the exception of vasectomy - Zona binding - MI to MII oocytes (must be MII at time of denudation)